{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:10:19Z","timestamp":1793855419349,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eclinm.2025.103246","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T07:57:51Z","timestamp":1747727871000},"page":"103246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"84","author":[{"given":"Zhou","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetiana","family":"Povshedna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Ready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene C.F.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie C.M.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3978-7624","authenticated-orcid":false,"given":"Elizabeth M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2025.103246_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","article-title":"A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies","volume":"71","author":"Curno","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103246_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/09540121.2015.1124984","article-title":"Side effects, adherence self-efficacy, and adherence to antiretroviral treatment (ART): a mediation analysis in a Chinese sample","volume":"28","author":"Zhang","year":"2016","journal-title":"AIDS Care"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103246_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ijpp\/riac052","article-title":"The influence of adverse drug effects on health-related quality of life in chronic obstructive pulmonary disease patients","volume":"30","author":"Altawalbeh","year":"2022","journal-title":"Int J Pharm Pract"},{"key":"10.1016\/j.eclinm.2025.103246_bib5","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6113.1000218","article-title":"Antiretroviral therapy (ART) side effect impacted on quality of life, and depressive symptomatology: a mixed-method study","volume":"4","author":"Chen","year":"2013","journal-title":"J AIDS Clin Res"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103246_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103246_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eimc.2020.02.018","article-title":"Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice","volume":"39","author":"Povar-Echeverr\u00eda","year":"2021","journal-title":"Enferm Infecc Microbiol Cl\u00edn (Engl Ed)"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103246_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/0956462416688127","article-title":"Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital","volume":"28","author":"Todd","year":"2017","journal-title":"Int J STD AIDS"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103246_bib10","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1097\/QAD.0000000000001279","article-title":"Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice","volume":"30","author":"de Boer","year":"2016","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103246_bib11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s43440-023-00515-y","article-title":"Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies","volume":"75","author":"Jakimiuk","year":"2023","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103246_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103246_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/hiv.13428","article-title":"Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic","volume":"24","author":"Mwebaza","year":"2023","journal-title":"HIV Med"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103246_bib14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","article-title":"Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review","volume":"21","author":"P\u00e9rez-Valero","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103246_bib15","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting","volume":"72","author":"Pe\u00f1afiel","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103246_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/aid.2020.0078","article-title":"Overall tolerability of integrase inhibitors in clinical practice: results from a multicenter Italian cohort","volume":"37","author":"Ciccullo","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103246_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25227","article-title":"Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort","volume":"22","author":"Mondi","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103246_bib18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/jac\/dkad026","article-title":"Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study","volume":"78","author":"D'arminio Monforte","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103246_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1550-8579(07)80025-8","article-title":"Antiretroviral pharmacokinetic profile: a review of sex differences","volume":"4","author":"Ofotokun","year":"2007","journal-title":"Gend Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103246_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103246_bib21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2165\/00002018-200528120-00003","article-title":"Sex differences in antiretroviral therapy-associated intolerance and adverse events","volume":"28","author":"Clark","year":"2005","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103246_bib22","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1086\/324088","article-title":"Sex differences in nevirapine rash","volume":"33","author":"Wong","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103246_bib23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00126334-200310010-00008","article-title":"Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study","volume":"34","author":"Murri","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103246_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/QAI.0b013e3181b628be","article-title":"Gender differences in discontinuation of antiretroviral treatment regimens","volume":"52","author":"Mirjam-Colette","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103246_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/apc.2021.0089","article-title":"Durability of dolutegravir-based regimens: a 5-year prospective observational study","volume":"35","author":"Taramasso","year":"2021","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eclinm.2025.103246_bib26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103246_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fgwh.2021.637398","article-title":"Medication adherence after acute coronary syndrome in women compared with men: a systematic review and meta-analysis","volume":"2","author":"Bots","year":"2021","journal-title":"Front Glob Womens Health"},{"key":"10.1016\/j.eclinm.2025.103246_bib29","series-title":"Meta-Analysis of Event Outcomes: Guideline Methodology Document 3","author":"Daly","year":"2021"},{"key":"10.1016\/j.eclinm.2025.103246_bib32","series-title":"Review Manager 5 (RevMan 5) [Computer program]. Version 5.4","year":"2020"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103246_bib33","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1111\/hiv.12540","article-title":"Morning dosing for dolutegravir-related insomnia and sleep disorders","volume":"19","author":"Capetti","year":"2018","journal-title":"HIV Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103246_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jac\/dky497","article-title":"Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort","volume":"74","author":"Cuzin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2025.103246_bib35","author":"Digaetano"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103246_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/v15040924","article-title":"Efficacy, convenience, safety and durability of DTG-based antiretroviral therapies: evidence from a prospective study by the Italian MaSTER cohort","volume":"15","author":"Fusco","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.eclinm.2025.103246_bib37","author":"Hoffman"},{"issue":"S5","key":"10.1016\/j.eclinm.2025.103246_bib38","first-page":"57","article-title":"Discontinuation of dolutegravir-containing regimens due to adverse reactions: real-world data","volume":"20","author":"Mohammed","year":"2019","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103246_bib39","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/QAD.0000000000002533","article-title":"Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients","volume":"34","author":"Nasreddine","year":"2020","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103246_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/25787489.2021.2003132","article-title":"Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study","volume":"22","author":"Pelchen-Matthews","year":"2021","journal-title":"HIV Res Clin Pract"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103246_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/v14051028","article-title":"Reversibility of central nervous system adverse events in course of art","volume":"14","author":"Taramasso","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103246_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3851\/IMP3351","article-title":"Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine\/tenofovir alafenamide in clinical practice","volume":"25","author":"Hoffmann","year":"2020","journal-title":"Antivir Ther"},{"issue":"S3","key":"10.1016\/j.eclinm.2025.103246_bib43","article-title":"Gender-related differences in safety after switching to BICTEGRAVIR\/TAF\/FTC in \u201creal life\u201d","volume":"22","author":"Moreno","year":"2021","journal-title":"HIV Med"},{"issue":"7414","key":"10.1016\/j.eclinm.2025.103246_bib44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103246_bib45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/QAI.0000000000000084","article-title":"Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States","volume":"66","author":"Hughes","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9868","key":"10.1016\/j.eclinm.2025.103246_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"issue":"10167","key":"10.1016\/j.eclinm.2025.103246_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"issue":"9936","key":"10.1016\/j.eclinm.2025.103246_bib48","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"issue":"10107","key":"10.1016\/j.eclinm.2025.103246_bib49","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103246_bib50","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1210\/clinem\/dgad411","article-title":"Weight gain after HIV therapy initiation: pathophysiology and implications","volume":"109","author":"Chandiwana","year":"2024","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.eclinm.2025.103246_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103246_bib52","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor\u2013based antiretroviral therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103246_bib53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/QAD.0000000000003514","article-title":"Inclusion of women in HIV research and clinical trials","volume":"37","author":"Johnston","year":"2023","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103246_bib54","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/QAD.0000000000003478","article-title":"Participation of HIV-1 infected treatment-naive females in clinical trials and sex differences in efficacy and safety outcomes","volume":"37","author":"Zhou","year":"2023","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103246_bib55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bcp.12639","article-title":"Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients","volume":"80","author":"Zhang","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103246_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103246_bib57","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ebiom.2015.05.012","article-title":"Investigation of efavirenz discontinuation in multi-ethnic populations of HIV-positive individuals by genetic analysis","volume":"2","author":"Cummins","year":"2015","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103246_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/QAI.0b013e3181609da8","article-title":"Ethnicity, race, and gender: differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST study)","volume":"47","author":"Tedaldi","year":"2008","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025001786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:01Z","timestamp":1760215741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025001786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":53,"alternative-id":["S2589537025001786"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103246","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103246"}}